e-limbo, e-zine de informacion y analasis de modos de vida actual
08.03.2021 / Sesión no Iniciada 

 _enviar articulo

e-mail emisor
e-mail receptor
Ayúdanos a evitar contactos automáticos
Anti Spam

En estos tiempos de hipercomunicación bastaría la invitación de enviar a un amigo cualquiera de los textos que consideres interesantes algo redundante: demasiada comunicación, demasiados textos y , en general, demasiado de todo.
Es posible que estemos de acuerdo... pero cuando encuentras algo interesante en cualquier sitio, la red, la calle, tu casa, o un lugar escondido y remoto, compartirlo no sólo es un acto (acción, hecho) de amistad o altruismo, también es una manera de ahorrar tiempo a los demás (y de que te lo ahorren a ti (si eres afortunado) a costa del tiempo que tu has podido derrochar (emplear) y el gustazo de mostrar que estuviste ahí (o donde fuera ) un poco antes (el tiempo ya no es más el que era).
Comparte con tus conocidos aquello que encuentras, es evolución.
Prescribing Drugs a Healthy Future
30-01-06 Edwin Colyer 


by Edwin Colyer

Rebranding is part of everyday life. Our favorite drinks get "improved," airlines change their signature colors, and even stores change their names, or at least their livery and layout, once in a while. We expect rebranding to happen. Sometimes we like it, sometimes we don't.
"But consumers are fickle," says Jon Parton, director of global branding at pharmaceutical company AstraZeneca. "If your product is not the newest and the best, then consumers will try something else. The market expects innovation and companies don't have to prove their new claims. If you don't keep up with new improved formulas and fashionable logos, then you will lose customers.

"In medicine this doesn't seem to apply," Parton continues. "To be better than the competition you have got to prove it with clinical studies and scientific data. There is not much an old product can do to compete with drugs that can prove their superiority."

This is Parton's way of saying that drug rebranding tends to be a bad idea. "You can't just do a 'bit of branding,' " he says. "Good branding must involve time and money. The idea that you could do some branding and squeeze out some extra revenue is wrong, especially at the end of a product's lifecycle when it faces competition from both generic products and newer prescription compounds."

Nevertheless, Parton concedes that brands must be maintained, adapted, and adjusted throughout their lives. "Marketers try to predict and respond to the environment that the product is competing in. For example, if a competitive product comes out and threatens it, you may have to change what you say and change what people think about your positioning. Or you may get approval for a new indication and that may completely alter what you say about your drug."

The osteoporosis drug Fosamax, for example, was originally marketed to specialist physicians who could prescribe it to post-menopausal women diagnosed with osteoporosis. However, in 2000, the FDA approved a once-a-week drug that could be used for the prevention of the disease. Fosamax's focus then moved from treatment to prevention; the main marketing audience became the primary care physician. The brand's messages had to change.

Mike Rea, managing director of pharmaceutical marketing firm IdeaPharma, argues that these kinds of "brand changing" events can be predicted and planned for. "You have to plan ahead. The alternative is not to—and wait for your marketing to turn around and bite you. Clearly you never know everything, but you can identify areas where you don't know enough and plan for various scenarios. For example, you may realize that some indications are not ready for your drug and you may need to do some market shaping well in advance of any launch."

Rea points to Lipitor as one of the best examples of a well planned brand. The world's top-selling statin (a drug used to lower cholesterol) was actually first approved for patients with a rare, often fatal disease called familial hypercholesterolemia. "It was a small commercial opportunity, but a real stepping stone," says Rea. "The halo effect was tremendous and helped Lipitor's success. I'm sure that they always intended leap-frogging to a 'mass market' product and the Lipitor brand must have been developed with this in mind. With all the additional supplementary approvals for Lipitor, the branding and messages have never really changed."

Rob Dhoble, president of DAS Healthcare, says that the branding issues that arise at the end of a drug's life can certainly be planned well in advance. "There are two main routes you can take to extend sales at the end of a drug's patent-protected life. One way is to couple the product to an additional patent, for example a novel drug delivery technology. Otherwise you can transfer the product to the over-the-counter space, where it becomes more like a consumer product. In the latter case this depends on the proven safety of the compound."

Dhoble says that the branding work to extend the cholesterol drug Zocor's life began more than seven years before its patents ended. Merck identified the drug as a candidate for over-the-counter (OTC) switching. After several failed attempts to switch to OTC status, the drug (now branded as Zocor Heart-Pro) was finally approved for OTC sales in the UK in 2004.

But according to Dhoble, all the while Merck was waiting for OTC approval it was undertaking extensive branding work. Zocor's main claim as a prescription product was that it lowered "bad" cholesterol. But how can you demonstrate this for an OTC product unless customers take blood tests? Zocor Heart-Pro was also targeting a population of people that had a moderate risk of a cardiovascular event (heart attack or stroke)—people who today feel fine and tomorrow are whisked off in an ambulance. "Merck knew that it had to find a role for physicians and pharmacists with this drug despite it going OTC," says Dhoble.

A large part of the branding work actually targeted pharmacists, now the front line decision-makers and gatekeepers of Zocor Heart-Pro. They needed to engage with the brand and be educated about typical "at risk" populations who would supposedly benefit from taking the OTC drug.
Unsurprisingly, the OTC marketing tends to focus more on aspects of the treatment that don't need blood tests to measure. The message on McNeil's (the Johnson & Johnson company which manufactures Zocor Heart-Pro) website is clear: Zocor Heart-Pro helps to prevent heart attacks. "If you are at moderate risk (that's a one in ten to one in seven risk of a heart attack in the next ten years)," the site copy reads, "you should be able to buy Zocor Heart-Pro from your pharmacist. It's great news for everyone who wants to take control of their heart health. After all, it is the single biggest step you can take without a prescription to lower your bad cholesterol and protect a healthy blood flow to your heart."

McNeil offers training and education materials for pharmacists and leaflets for patients. Patients are also invited to engage with the brand by joining the "Healthy Heart Program" and monitoring any adverse events.

Despite this shift in emphasis, however, the Zocor Heart-Pro brand also remains loyal to its origins. In the US, where the drug remains a prescription-only medicine, the brand also promises to save lives: "Zocor does more than just lower cholesterol," it says on the US product website. "Zocor helps save lives."

"Even if a drug does not go OTC, but is modified with a drug delivery system, the branding challenge is not small," says Dhoble. "You want familiarity between the old and the new, but you don't want them to be equivalent. Unless you do a good job, the product will not be approved for reimbursement or make it onto national formularies."

But while the end of a drug's life can be anticipated, AstraZeneca's Parton points out that accurately mapping its entire lifecycle is far removed from laboratory science. "Long-term strategic planning is what we aspire to do. But the further out we get from the present the more likely we are to be wrong. We are confident with the short-term, but anything over five years is almost impossible to predict."

Dhoble blames much of this unpredictability on the way the industry is so heavily regulated. "While there's a lot of wisdom in long-term branding based on a full clinical development plan, there are so many variables that the certainty of what such a plan represents is diminished," he says. "In the pharma world the decisions are not your own. If a big food company wanted to bring out an active nutrition bar for men over 50 it could probably launch one within six months. Pharma companies have to go through scientific trials, then regulatory scrutiny. It is all about safeguarding public health, and there are no certainties at any step."

So sometimes, inevitably, the branding experts are called in to troubleshoot, says Dhoble. "Branding consultants can breathe life into a brand which hasn't changed from a product point of view. It tends to happen where a product represents a large proportion of a company's turnover, or several products are considered as a group."

"If you know that you are not connecting with your audience, it would be foolish to keep banging the drum in the hope that it will eventually work," adds Rea, of IdeaPharma. "It is a hard call, but it does sometimes make sense. If you see the product going in the wrong direction or not breaking through and there is no apparent reason for that, then the only thing to change is the messaging and branding. And there is no better time to do it than now. People should bite the bullet, say they got it wrong and change it straight away."

Rea points to Seroquel, an antipsychotic: "Five years ago this was an awful brand. It has been turned around. They didn't play around with the imagery, just got the basics right, clarifying messages and making sure that promises were delivered."

But he argues that this kind of rebranding should not need to happen. "The best brands in the pharmaceutical world are those that do not change from five years pre-launch to long after patent expiry," he says, "but this is only possible if the brands are actively monitored and managed. Branding is usually considered pre-launch and if it doesn't do well, then companies think about doing some more three to five years in. Often there is no active process to manage the brand."

This is why brands begin to drift. They stray from their core values, or they do not address unforeseen changes in the market. "When brand performance is ignored you may have to resort to rebranding. Then high level changes are always risky and could just as easily fail," says Rea. "Low level changes may just be mere tinkering, giving someone in marketing something to do between 9 and 5."

Dhoble says that pharma companies need to see their relationships with branding experts in the same way that they consider their advertising agencies. "It is better for a client to have a continuous branding operation in place with contingencies built in and 'what ifs' accounted for. Instead of wondering whether one branding agency could give something that another agency didn't, pharma companies should look at building ongoing relationships." Active brand management, he suggests, could avoid the need for much of the troubleshooting and keep pharma brands looking healthy for the whole of their lives.


Rating: 4 - 1 voto(s).

No existen comentarios.
Comentario / Comment:
  atención: para realizar comentarios tienes que ser usuario registrado.


15-01-12_ "Recapitalizar a los bancos por tener deuda de su país es absurdo"
24-01-11_ Sociedad Estatal de Demoliciones Culturales
18-09-09_ LA comercialización de la cultura
26-10-08_ Solbes: «2009 va a ser peor, no cabe la menor duda»
02-01-09_ The Story of Stuff
05-10-08_ SOROS * entrevista
21-05-08_ Why People Don't Trust Free Markets
02-05-08_ Zimbabue compra por Internet para sortear una inflación del 100.000%
24-03-08_ IDEIA DEKOT * Manual de supervivencia para montártelo por tu cuenta
04-02-08_ ¿'CRACK' 2008?
24-03-08_ Copia privada, ese derecho virtual
24-03-08_ The Pirate's Dilemma: A Review
23-12-07_ Así en la SGAE como en la Iglesia
17-12-07_ Dos asociaciones denuncian que la SGAE financia al poder judicial
16-12-07_ RECIPE: Five Great Lunchbox Favs
25-11-07_ Invitation to the OpenBusiness Community
15-11-07_ Trade-offs of offering content for free
16-11-07_ Climate change * from issue to magnifier
22-10-07_ SGAE: la punta del iceberg de un entramado societario...
02-11-07_ La JUSTICIA y el P2P ( ¡! )
14-09-07_ Executive Compensation: Is This the Beginning of a New Era?
06-07-07_ Collapse: How the U.S. Is Choosing to Fail
26-06-07_ The market function of piracy
24-05-07_ Seven gay wonders of the world
29-08-07_ Designig for Humans Not Users
31-05-07_ Introducing... the starving artist
31-05-07_ Martín Patino liberará su Filmografía.
31-05-07_ People Inside Web 2.0: An Interview with Tim O'Reilly
29-05-07_ Rutas para la innovación abierta: costes, aceleración y creatividad
26-03-07_ WEB 2.0 según TechCrunch
24-03-07_ Arcadi Espada y el Canon
17-03-07_ Ni se le ocurra tatarear a Mozart
15-03-07_ ¿Cómo hacer un blog de economía?
13-03-07_ El brujo de Menlo Park
03-03-07_ Mobile the 7th Mass Media is to internet like TV is to radio
23-02-07_ Hacia el fin del COPYRIGHT
18-02-07_  Shit Help Bad Hot Army Boom Kill!!! 
07-02-07_ Pensamientos sobre la música * Steve Jobs
04-02-07_ MOD Films
03-02-07_ Si no te conectas es por que no quieres...
30-01-07_ Emerging Art Markets
27-01-07_ The "special interests" destroying China's environment
17-01-07_ La SGAE vista desde dentro...
16-01-07_ Interview * Michael Bauwens
10-01-07_ Pero plagiar es otra cosa
04-01-07_ Amenazas a la información

04-01-07_ Los Múltiples retos de la innovación
28-12-06_ Comprando Burgos, La ciudad...
25-12-06_ The inexplicable inexistence of Real Madrid
11-12-06_ Openstudio * Experimento en creatividad, colaboración y capitalismo.
03-12-06_ Open Business re-crea la comunidad
27-11-06_ Cafuné breaking the limits for Open Business models
23-11-06_  Business Model Template Hacking
18-11-06_ O.J. Simpson, News Corp, and Milton Friedman
13-11-06_ Stray Cinema
01-11-06_Del Elitismo de la Web 1.0 a la Burbuja 2.0
01-11-06_How Non-Commercial Licenses make Business
26-10-06_He vuelto de Ikea y mi único deseo es matar (I)
25-10-06_A new idea about Opening Business
19-10-06_Revver - Openbusiness New Sponsor
08-10-06_Is Your Personality the Ticket to Financial Freedom?
30-09-06_The Wrong Gallery * The greatest little gallery on earth
22-09-06_el sin-sentido de las patentes
21-09-06_Open Business Meets Filmaking
16-09-06_IndieKarma * a new way to get paid for blogging
09-09-06_Revolution at our fingertips
08-09-06_La 'wikimanía' se extiende por la Red
01-09-06_Copyright Criminals: This is a Sampling Sport
31-08-06_Man From Google Joins Apple’s Board
18-08-06_Patents for profit: dystopian visions of the new economy
13-08-06_The cluetrain manifesto
10-08-06_Depositos finacieros, vivienda y deducción fiscal
07-08-06_YOU TUBE * me watch
05-08-06_Reunión mundial de piratas informáticos en Las Vegas
04-08-06_Lo que les preocupa a los poderosos
13-03-07_ Ya hay más de 500.000 firmas contra el canon digital
23-07-06_Con la moral por delante
22-07-06_Gateway to Nowhere?
21-07-06_Industria musical y cultura libre: hoy en el CCCB
30-06-06_People Power
15-06-06_El futuro del libro: líquido o en la Red
13-06-06_Casas que están vivas
05-06-06_The fall and rise of Kate Moss
24-05-06_Primera Gran Guerra por el control de la Red
23-05-06_The sunset stalker: Bono
06-06-06_The greedy truth about media consultants
07-06-06_Making meaning from our own stories (Selflore) in the age of discontinuity
22-04-06_La crítica en la era del capitalismo cultural electrónico
05-04-06_La SGAE bate su propio récord de ingresos... y +++
29-03-06_How Copyright Law Changed Hip Hop
03-05-06_China acapara ya el 19% de las reservas internacionales de divisas
25-03-06_Intellectual Property roundup
24-03-06_De Gutenberg a Amazon: cómo convertirse en autor de verdad, sin salir de casa
19-03-06_La mala política energética de Bush
17-03-06_Los estudiantes franceses vuelven a la calle
16-03-06_Brent Hoberman:
06-03-06_Los ‘sukuk’, o cómo invertir sin ofender los mandamientos del profeta
06-03-06_More power to you
18-02-06_I Do, I Do, I Do, I Do
02-03-06_Trabajo afectivo
13-02-06_El parlamento de las cosas
19-03-06_Entrevista: Sabine Breitwieser
07-02-06_El dividendo del arte
03-02-06_Adieu Alan, Bonjour Ben, Welcome Transparency
30-01-06_ Prescribing Drugs a Healthy Future
20-01-06_Vers la décroissance: Écofascisme ou écodémocratie
27-01-06_The New Market Bubble Theory
16-01-06_We need a new drug (system)
13-01-06_Garçon! Un Coca-Cola, S'il Vous Plaît
09-01-06_Weather Has Become Bogeyman, News Staple
07-01-06_La inmigración en España / Una obsesión desbordada
04-01-06_Novel Thinking as a Survival Tactic
27-12-05_África, un desacuerdo navideño con Bono
23-12-05_America's most-hated companies
21-12-05_¡Tu Mismo!
03-12-05_El bajo perfil de España en Estados Unidos
29-09-05_Infinita Avaricia
22-06-05_Por ahí
09-06-05_¡Tu Mismo!



Regístrate y disfruta de utilidades de administración y gestión de los contenidos de e-limbo*
Recibe las novedades en tu correo electronico.
El futuro está escrito en las estrellas... Horóscopo creado por J.G. Ballard y dedicado a todos vosotros.
Aplicaciones y herramientas necesarias para navegar y utilizar los contenidos del limbo electrónico e internet (www).
Artículos de e-limbo* en formato PDF preparados para viajar y aportar información allá donde estés. (y seguir salvando árboles)

_e-limbo * apoya



Mais uma edição do podcast Música Livre para o Archivo Vivo, do Centro Cultural da Espanha/AECID. ...
Ante preguntas de oyentes y amigos, puedo responder ahora que Vía Límite continuará en Radio ...
SORPRESA¡!¡! An unreleased version of Talking Heads' "Psycho Killer" with Arthur Russell on cello
Optimizado: Firefox, Safari, Mozilla, Netscape, Konqueror, Explorer. Resolución óptima: 1024x768
ISSN: 1885-5229    Aviso Legal e-limbo.org*